Skip to main content
. 2022 Oct 14;10(10):2583. doi: 10.3390/biomedicines10102583
AS Active surveillance
ASA American Society of Anesthesiology
ASCO American Society of Clinical Oncology
AUA American Urological Association
CA Cryoablation
CT Computed tomography
DFS Disease-free survival
DISSRM Delayed Intervention and Surveillance of Small Kidney Masses
DSS Disease-specific survival
EAU European Association of Urology
eGFR Estimated glomer
FDA Food and Drug Administration
FT Focal therapy
IRE Irreversible electroporation
MFS Metastasis-free survival
MWA Microwave ablation
NCCN National Comprehensive Cancer Network
OS Overall survival
PE Primary efficacy
PFS Progression-free survival
PN Partial nephrectomy
RCC Renal cell carcinoma
RFA Radiofrequency ablation
RFS Recurrence-free survival
RN Radical nephrectomy
SE Secondary efficacy
SOC Standard of care
SRM Small renal masses
TA Thermal ablation